EDAP Installs First Ablatherm Robotic HIFU Device in the Netherlands Continuing European Expansion

LYON, France, Sep 10, 2008 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the launch of initial HIFU services at Amphia Ziekenhis Hospital, in Breda, the first Ablatherm robotic HIFU treatment center in the Netherlands.

Dr. Harald Janssen, Head of the Urology Deptartment at Amphia Ziekenhis Hospital, in Breda, Netherlands, commented, "The Ablatherm device will enable our center to be at the forefront of the treatment of prostate cancer with the latest technologies. I have been impressed with the technology and the minimally invasive approach of the Ablatherm-HIFU system. Our first patients were successfully treated with no complications, following a comprehensive training program under EDAP's leadership. We have additional patients scheduled for treatment and I look forward to expanding the number of treatment volumes at Amphia Ziekenhis to those patients suffering from localized prostate cancer."

"We are excited to launch the first HIFU site in the Netherlands offering patients the opportunity to benefit from the advantages of Ablatherm-HIFU therapy in the treatment of localized prostate cancer," said Jean-Francois Bachelard, EDAP's Business Unit Director. "Clinical teams in the Netherlands are very enthusiastic about the technology and the benefits offered to patients. We expect to expand our HIFU RPP services to several sites in the Netherlands using Amphia's Ablatherm system on a mobile basis. Two hospitals have already commenced EDAP's training program and expect to start treating patients within the next few weeks. Other clinical sites are also expected to participate in the coming months."

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We are very pleased by the growing adoption of Ablatherm-HIFU across Europe, as exemplified by our opening of a new country to the benefits of Ablatherm as a proven non-invasive therapeutic solution for prostate cancer. This marks a clear milestone for our technology and serves as a clear recognition of EDAP's growth potential for entering new European markets. We look forward to driving HIFU treatment volumes in the Netherlands with the expected addition of two new centers in the country on a mobile RPP basis. We are excited to see the positive success of our sales and marketing strategy that continues to increase the awareness and adoption of our products throughout Europe."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com or http://www.urotoday.com/HIFU.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS S.A.

EDAP TMS SA

Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com

The Ruth Group
Investors:
R.J. Pellegrino
646-536-7009
rpellegrino@theruthgroup.com

News Provided by COMTEX